|
1
|
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
|
N Engl J Med
|
2013
|
7.29
|
|
2
|
Hypophosphatemia: an evidence-based approach to its clinical consequences and management.
|
Nat Clin Pract Nephrol
|
2006
|
1.98
|
|
3
|
What nephrologists need to know about gadolinium.
|
Nat Clin Pract Nephrol
|
2007
|
1.60
|
|
4
|
Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial.
|
J Am Coll Cardiol
|
2012
|
1.43
|
|
5
|
Predictors of hyperkalemia and death in patients with cardiac and renal disease.
|
Am J Cardiol
|
2012
|
1.42
|
|
6
|
Rhabdomyolysis: a review, with emphasis on the pediatric population.
|
Pediatr Nephrol
|
2010
|
1.08
|
|
7
|
Unfractionated heparin for hemodialysis: still the best option.
|
Semin Dial
|
2010
|
1.07
|
|
8
|
Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences.
|
Clin J Am Soc Nephrol
|
2011
|
1.06
|
|
9
|
Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
|
Semin Dial
|
2008
|
1.02
|
|
10
|
Hereditary disorders of renal phosphate wasting.
|
Nat Rev Nephrol
|
2010
|
0.98
|
|
11
|
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
|
Am J Cardiol
|
2011
|
0.96
|
|
12
|
Hereditary etiologies of hypomagnesemia.
|
Nat Clin Pract Nephrol
|
2008
|
0.94
|
|
13
|
Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality.
|
Am J Cardiol
|
2008
|
0.89
|
|
14
|
Heparin-induced thrombocytopenia: a renal perspective.
|
Nat Rev Nephrol
|
2009
|
0.88
|
|
15
|
Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease.
|
Semin Dial
|
2003
|
0.87
|
|
16
|
Non-pharmacological aspects of blood pressure management: what are the data?
|
Kidney Int
|
2011
|
0.85
|
|
17
|
Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.
|
Semin Dial
|
2008
|
0.84
|
|
18
|
Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection.
|
Nephrology (Carlton)
|
2005
|
0.83
|
|
19
|
Vascular access surveillance: evaluation of combining dynamic venous pressure and vascular access blood flow measurements.
|
Am J Nephrol
|
2003
|
0.83
|
|
20
|
Spondylodiscitis in a patient on chronic hemodialysis.
|
Nat Rev Nephrol
|
2011
|
0.81
|
|
21
|
Imaging patients with kidney disease: how do we approach contrast-related toxicity?
|
Am J Med Sci
|
2011
|
0.80
|
|
22
|
Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?
|
Clin J Am Soc Nephrol
|
2012
|
0.80
|
|
23
|
Primary care approach to proteinuria.
|
J Am Board Fam Med
|
2008
|
0.79
|
|
24
|
Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
|
Nephrology (Carlton)
|
2006
|
0.78
|
|
25
|
Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion?
|
Int Urol Nephrol
|
2010
|
0.77
|
|
26
|
Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
|
Semin Dial
|
2011
|
0.76
|
|
27
|
Risk factors: filling in the gap.
|
Nat Rev Nephrol
|
2012
|
0.75
|
|
28
|
Anticoagulation and continuous renal replacement therapy.
|
Semin Dial
|
2006
|
0.75
|
|
29
|
Are calcium-based phosphate binders ever preferable in dialysis patients?
|
Semin Dial
|
2014
|
0.75
|
|
30
|
Does the risk exceed the benefit for anticoagulation in end-stage renal disease patients with nonrheumatic atrial fibrillation?
|
Semin Dial
|
2011
|
0.75
|
|
31
|
Hungry bone syndrome.
|
Curr Opin Nephrol Hypertens
|
2017
|
0.75
|